Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 3 , Pages 204-210 , July 2007

Burden of illness among commercially insured patients with Alzheimer’s disease

  • Amie T. Joyce

      Affiliations

    • PharMetrics Inc (a unit of IMS), Watertown, MA, USA
    • ,
  • Yang Zhao

      Affiliations

    • Eli Lilly & Co, Indianapolis, IN, USA
    • ,
  • Lee Bowman

      Affiliations

    • Eli Lilly & Co, Indianapolis, IN, USA
    • ,
  • Jennifer A. Flynn

      Affiliations

    • Eli Lilly & Co, Indianapolis, IN, USA
    • ,
  • Chureen T. Carter

      Affiliations

    • PharMetrics Inc (a unit of IMS), Watertown, MA, USA
    • Dr Carter is now employed by Ortho Biotech, LLC, Raritan, NJ, USA.
    • ,
  • Daniel A. Ollendorf

      Affiliations

    • PharMetrics Inc (a unit of IMS), Watertown, MA, USA
    • Corresponding Author InformationCorresponding author. Tel.: 617-393-8322; Fax: 617-972-8587.

References 

  1. Bird TD. Alzheimer’s disease and other primary dementias. In:  Braunwald E,  Fauci A,  Hauser S,  Jameson J,  Kapser D, et al. editor. Harrison’s principles of internal medicine. 15th ed.. New York: McGraw Hill; 2001;p. 2391–2398
  2. Rice DP, Fillit HM, Max W, Knopman DS, Lloyd JR, Duttagupta S. Prevalence, costs, and treatment of Alzheimer’s disease and related dementia: a managed care perspective. Am J Manag Care. 2001;7:809–818
  3. Statistics about Alzheimer’s disease. Available at: http://www.alz.org/AboutAD/Statistics.htm. Alzheimer’s Association, 2004. Accessed September 23, 2004.
  4. Causes of Alzheimer’s disease. Available at: http://www.alzheimers.org/causes.htm. Alzheimer’s Disease Education and Referral Center, 2004. Accessed September 23, 2004.
  5. Losing a million minds: confronting the tragedy of Alzheimer’s disease and other dementias. Washington, DC: US Congress Office of Technology Assessment, U.S. Government Printing Office; 1987;
  6. Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, et al. The economic burden of Alzheimer’s disease care. Health Affairs. 1993;12:164–176
  7. Medicare and Medicaid costs for people with Alzheimer’s disease. Washington, D.C: Alzheimer’s Association; 2001;
  8. Heart disease burden: chronic disease notes and reports. Atlanta: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health; 2004;
  9. Diabetes Self Management Training Act of 2005. Available at: http://www.theorator.com/bills109/s626.html. Data referenced in bill presented to the US 109th Congress, 1st session, S. 626, March 15, 2005. Accessed: June 16, 2005.
  10. 2001-2002 Alzheimer’s disease progress report. Bethesda, MD: National Institutes of Health; 2003;Publication number 03-5333
  11. Leon J, Neumann PJ. The cost of Alzheimer’s disease in managed care: a cross-sectional study. Am J Manag Care. 1999;5:867–877
  12. Gutterman EM, Markowitz JS, Lewis B, Fillit H. Cost of Alzheimer’s disease and related dementia in managed Medicare. J Am Geriatr Soc. 1999;47:1065–1071
  13. Fillit H, Hill JW, Futterman R. Health care utilization and costs of Alzheimer’s disease: the role of comorbid conditions, disease stage, and pharmacotherapy. Fam Med. 2002;34:528–535
  14. Martin BC, Ricci JF, Kotzan JA, Lang K, Menzin J. The net cost of Alzheimer disease and related dementia: a population-based study of Georgia Medicaid recipients. Alzheimer Dis Assoc Disord. 2000;14:151–159
  15. Hill JW, Futterman R, Duttagupta S, Mastey V, Lloyd JR, Fillit H. Alzheimer’s disease and related dementias increase costs of comorbidities in managed Medicare. Neurology. 2002;58:62–70
  16. Richards KM, Shepherd MD, Crimson ML, Snyder EH, Jermain DM. Medical services utilization and charge comparisons between elderly patients with and without Alzheimer’s disease in a managed care organization. Clin Ther. 2000;22:775–791
  17. Menzin J, Lang K, Friedman M, Neumann P, Cummings JL. The economic cost of Alzheimer’s disease and related dementias to the California Medicaid Program (“Medi-Cal”) in 1995. Am J Geriatr Psychiatry. 1999;7:300–308
  18. Rigaud AS, Fagnani F, Bayle C, Latour F, Traykov L, Forette F. Patients with Alzheimer’s disease living at home in France: costs and consequences of the disease. J Geriatr Psychiatry Neurol. 2003;16:140–145
  19. Beeri MS, Werner P, Adar Z, Davidson M, Noy S. Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord. 2002;16:73–80
  20. Atance Martinez JC, Yusta Izquierdo A, Grupeli Gardel BE. Costs study in Alzheimer’s disease. Rev Clin Esp. 2004;204:64–69
  21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–383
  22. McCullagh P, Nelder JA. Generalized linear models. London: Chapman and Hall; 1989;

PII: S1552-5260(07)00467-0

doi: 10.1016/j.jalz.2007.04.373

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 3 , Pages 204-210 , July 2007

Article Tools